A phase II study of bleximenib monotherapy (NCT04811560, namely a cAMeLot-1 study) in R/R AML patients with KMT2Ar or NPM1 alterations is ongoing [132]. The gene discussed is NPM1; the disease is acute myeloid leukemia.